Tyra Biosciences, Inc. Loss Contingency Accrual
Tyra Biosciences, Inc. (TYRA) had Loss Contingency Accrual of $0 as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes
us-gaap:LossContingencyAccrualAtCarryingValue · last filed 2022-11-03
- 2022-09-30: Loss Contingency Accrual $0.00.
- 2022-06-30: Loss Contingency Accrual $0.00.
- 2022-03-31: Loss Contingency Accrual $0.00.
- 2021-12-31: Loss Contingency Accrual $0.00.
| Period end | Loss Contingency Accrual |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-03 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-03 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |